Inducing Cytotoxicity in Colon Cancer Cells and Suppressing Cancer Stem Cells by Dolasetron and Ketoprofen through Inhibition of RNA Binding Protein PUM1

Clinical trials of new drugs often face a high failure rate of approximately 45 percent due to safety and toxicity concerns. Repurposing drugs with well-established safety profiles becomes crucial in addressing this challenge. Colon cancer ranks as the third most prevalent cancer and the second lead...

Descripción completa

Detalles Bibliográficos
Autores principales: Gor, Ravi, Gharib, Ali, Dharshini Balaji, Priya, Madhavan, Thirumurthy, Ramalingam, Satish
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10458631/
https://www.ncbi.nlm.nih.gov/pubmed/37624174
http://dx.doi.org/10.3390/toxics11080669

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10458631/
https://www.ncbi.nlm.nih.gov/pubmed/37624174
http://dx.doi.org/10.3390/toxics11080669

Ejemplares similares